The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
 
Amin Nassar
No Relationships to Disclose
 
Elio Adib
Employment - Amgen (I)
 
Jamie Feng
Honoraria - AstraZeneca Canada
 
Jacqueline V. Aredo
No Relationships to Disclose
 
Kaushal Parikh
Consulting or Advisory Role - Guardant Health; Jazz Pharmaceuticals (Inst); MJH Life Sciences
Research Funding - Pfizer
 
Jeremy Phillip Harris
No Relationships to Disclose
 
Ana I. Velazquez Manana
Stock and Other Ownership Interests - Corbus Pharmaceuticals
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Bio Ascend; DAVA Oncology
Other Relationship - Pfizer
 
Meera Vimala Ragavan
No Relationships to Disclose
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - Bayer; Blueprint Medicines; C4 Therapeutics; Elevation Oncology; Genentech; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Regeneron; Turning Point Therapeutics
Research Funding - Bayer (Inst); Elevation Oncology (Inst); Hengrui Therapeutics (Inst); Linnaeus Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Relay Therapeutics (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Zofia Piotrowska
Consulting or Advisory Role - AstraZeneca; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo Europe GmbH; Janssen; Lilly; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); ARIAD/Takeda (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline/Tesaro (Inst); GlaxoSmithKline/Tesaro (Inst); Janssen Oncology (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune
 
Bailey Gleason Fitzgerald
No Relationships to Disclose
 
Christian Grohé
No Relationships to Disclose
 
Kamya Sankar
No Relationships to Disclose
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; HMP Education; Medical Educator Consortium; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Calithera Biosciences; D2G Oncology; Exelixis; Genentech/Roche; Gilead Sciences; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Mirati Therapeutics; Natera; Novartis; Novocure; Regeneron; Sanofi/Regeneron; Summit Therapeutics; Surface Oncology; Takeda; Turning Point Therapeutics
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Heather A. Wakelee
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst); Xcovery (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Daiichi Sankyo; Merck Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Roy S. Herbst
Leadership - American Association for Cancer Research; IASLC; Immunocore; Junshi Pharmaceuticals; Society for Immunotherapy of Cancer; SWOG
Stock and Other Ownership Interests - Bolt Biotherapeutics; Checkpoint Therapeutics; Immunocore; Normunity
Consulting or Advisory Role - Abbvie; AstraZeneca; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics; Checkpoint Therapeutics; Cybrexa Therapeutics; DynamiCure Biotechnology; eFFECTOR Therapeutics; EMD Serono; Genentech/Roche; Gilead/Forty Seven; HiberCell; I-Mab; Immune-Onc Therapeutics; Janssen; Johnson and Johnson; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; NextCure; NextCure; Normunity; Novartis; Ocean Biomedical; OncoCyte; Oncternal Therapeutics; Pfizer; Refactor Health; Regeneron; Revelar; Ribon Therapeutics; Sanofi; Seagen; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
Travel, Accommodations, Expenses - American Cancer Society; IASLC; SWOG
 
Abdul Rafeh Naqash
No Relationships to Disclose
 
Sarah B. Goldberg
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genzyme; Janssen; Merck; Mirati Therapeutics; Regeneron; Summit Therapeutics; Takeda
Research Funding - Amgen (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Mirati Therapeutics; Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
So Yeon Kim
Consulting or Advisory Role - Amgen